832-497-2220 [email protected]

CNS 

According to the China Biotech Primer (2019), the central nervous system (CNS) therapeutic market in China is positioned in third place (US$14 billion with a CAGR of 5%), slightly behind oncology (US$17 billion with a CAGR of 9%). As one of the leading causes of ill-health and disability in China, CNS diseases now have a 238 million patient base with a lower than 20% diagnosis rate, showing that it is a high-potential market. An ageing population and urban expansion in China will accelerate its prevalence and incidence, which corroborates the medical burden CNS diseases will bring.

Submitted Projects:

Project ID: CNS100

Category: CNS

Keywords: Degenerative neurological disease drugs

Project/Product Summary:

This project focuses on drug development for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related diseases such as type 2 diabetes (T2D). The team uses a new drug screening technology to solve the biological stress (Biochemical Stress) problem in these diseases from the fundamental biological mechanism-including Oxidative Stress, Glyoxal Stress and Protein Aggregation stress and many more. Cantabio is now focusing on the development of new drugs in the small molecule chaperone category that will soon enter clinical testing. Cantabio’s core technical advantage in the global sense lies in its research and development capabilities for Intrinsically Disordered Proteins such as Tau and new protein targets such as DJ-1. DJ-1’s multifunctional characteristics have a systemic effect on biological stress.

 

Indications: Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related diseases such as type 2 diabetes (T2D)

Stage: Preclinical

Partnering Objective: Fundraising: 2-10 Million USD, JV, Co-development

Country: USA

Project ID: CNS101

Category: CNS

Keywords: Degenerative neurological disease drugs

Project/Product Summary:

Company’s candidate medicine Posiphen® targets early stage Parkinson’s Disease as well as Alzheimer’s Disease and may stop or slow the progression of those diseases. Posiphen® reduces levels of amyloid precursor protein (APP), tau and α-Synuclein (aSYN), three proteins that can turn toxic and precipitate the onset of neurodegeneration.

Posiphen® inhibits APP, tau and aSYN in tissue culture cells, mice as well as in humans. Posiphen® also shows promise in Huntington’s disease, Down Syndrome, Traumatic Brain Injury, and Post Operative Cognitive Decline. So far three clinical studies have been conducted with Posiphen®.”

Indications: Parkinson’s disease (PD), Alzheimer’s disease (AD) and other neurodegenerative diseases

Stage: Clinical Phase I

Partnering Objective: Fundraising, Licensing

Country: USA

Project ID: CNS102

Category: CNS

Keywords: Small molecule A3R activator

Project/Product Summary:

Project is brought by a small asset-centric CNS drug development company based in Cambridge, MA, USA.  The company has raised $4.7M in private financing and been awarded $4M in NIH grants.AST-004 is a novel small molecule A3R agonist that activates mitochondrial energy production in astrocytes and promotes multiple intrinsic neuroprotective mechanisms.

Indications: Acute ischemic stroke (AIS), traumatic brain injury (TBI) and concussion

Stage: Preclinical

Partnering Objective: Fundraising, Co-development

Country: USA